Jerome Dwyer, MD
Cardiology · Saint Louis, MONPI 1477515047
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,136 of the $14,202 with a category attached, or 64.3%. 25 manufacturers reported payments, led by Biotronik Inc. at 58.3% of the total. Reporting peaked in 2022 at $5,072 and has fallen 81.1% since, to $960 in 2025.
Across 284 payments — averaging $50.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$8K
- Novartis$1K
- Boston Scientific$840
- AstraZeneca$618
- E.r. Squibb & Sons, L.L.C.$428
- Kiniksa Pharmaceuticals, Ltd.$384
- plus $2K from 19 others
Across 11 payments — averaging $175.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotronik Inc.$2K
What the payments were for
- Consulting fees$1,87513%
- Travel & lodging$3,17722%
- Food & beverage$9,13664%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 64 | $8,283 |
| Novartis | 85 | $1,175 |
| Boston Scientific | 3 | $840 |
| AstraZeneca | 14 | $618 |
| E.r. Squibb & Sons, L.L.C. | 25 | $428 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $384 |
| Boehringer Ingelheim | 11 | $361 |
| Esperion Therapeutics, Inc. | 12 | $346 |
| Merck | 9 | $282 |
| Amgen | 9 | $269 |
| Johnson & Johnson | 13 | $238 |
| Cvrx, Inc. | 3 | $209 |
| Sanofi-aventis U.S. LLC | 8 | $163 |
| Pfizer | 8 | $131 |
| Janssen Scientific Affairs, LLC | 1 | $121 |
| Medtronic | 1 | $100 |
| Kestra Medical Technology Services, Inc. | 4 | $71 |
| Regeneron Healthcare Solutions, Inc. | 2 | $29 |
| Edwards Lifesciences | 1 | $25 |
| Abbott | 1 | $25 |
| Baxter Healthcare | 1 | $23 |
| Heartflow, Inc. | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BioMonitor$1,870
- Acticor 7 VR-T DX$1,426
- Solia$1,300
- Edora 8 DR-T$1,150
- Rivacor 7 DR-T$895
- WATCHMAN Access System$731
- AMVIA EDGE$530
- Rivacor$505
- Acticor$505
- Edora$505
- ARCALYST$363
- FARXIGA$245
- Barostim Neo System$169
- BRILINTA$125
- Passeo-18$125
- Orsiro Mission$125
- PRO-Kinetic Energy$125
- PK Papyrus$125
- NEXLIZET$123
- NEXLETOL$123
How this compares
Too few cardiology providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 141 | $134,190 |
| EntrestoSacubitril/Valsartan | 101 | $102,200 |
| XareltoRivaroxaban | 68 | $71,692 |
| FarxigaDapagliflozin Propanediol | 36 | $24,151 |
| PradaxaDabigatran Etexilate Mesylate | 11 | $2,129 |
| Metoprolol Succinate | 115 | $1,732 |
| ClopidogrelClopidogrel Bisulfate | 136 | $1,560 |
| Carvedilol | 175 | $1,511 |
| Atorvastatin Calcium | 82 | $1,018 |
| Rosuvastatin Calcium | 27 | $1,012 |
| Losartan Potassium | 104 | $968 |
| Potassium Chloride | 38 | $943 |
| Pravastatin Sodium | 71 | $727 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 25 | $550 |
| Lisinopril | 79 | $498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $131 | $134,190141 claims |
| NovartisEntresto | $1,175 | $102,200101 claims |
| Johnson & JohnsonXarelto | $238 | $71,69268 claims |
| AstraZenecaFarxiga | $618 | $24,15136 claims |
| Boehringer IngelheimPradaxa | $361 | $2,12911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Missourion file to place this against a meaningful peer group, so we don't.
Other cardiology in Saint Louis
- Lisa AldersonSaint Louis$2K
- Mark HuffmanSaint Louis$0
- David RawnsleySaint Louis$0
- Frank Seghatol-EslamiSaint Louis$0
- Philip LudbrookSaint Louis$0
- Karen Joynt MaddoxSaint Louis$0
- Homaa AhmadSaint Louis$0
- Thomas MaddoxSaint Louis$0
- Susan MayerKansas City$0
- James SearKansas City$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.